These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 11799188)

  • 1. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.
    Monath TP; Arroyo J; Levenbook I; Zhang ZX; Catalan J; Draper K; Guirakhoo F
    J Virol; 2002 Feb; 76(4):1932-43. PubMed ID: 11799188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
    Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
    J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
    Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
    J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecularly cloned, live-attenuated japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij Hairpin of the Viral E glycoprotein determines neurovirulence in mice.
    Yun SI; Song BH; Kim JK; Yun GN; Lee EY; Li L; Kuhn RJ; Rossmann MG; Morrey JD; Lee YM
    PLoS Pathog; 2014 Jul; 10(7):e1004290. PubMed ID: 25077483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.
    Yu Y
    Vaccine; 2010 May; 28(21):3635-41. PubMed ID: 20226891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel amino acid site closely associated with the neurovirulence of live, attenuated Japanese encephalitis vaccine (SA14-14-2 strain).
    Yang H; Fan F; Liu L; Liu J; Sun Y; Xie A; Shi X; Liu L; Yu Y; Li Y; Ge Y; Zeng X; Yang H
    Vaccine; 2020 Mar; 38(11):2636-2642. PubMed ID: 32044162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and neuroattenuation phenotypic characteristics and their stabilities of SA14-14-2 vaccine seed virus.
    Liu X; Zhao D; Jia L; Xu H; Na R; Ge Y; Liu S; Yu Y; Li Y
    Vaccine; 2018 Jul; 36(31):4650-4656. PubMed ID: 29954631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2.
    Yang D; Li XF; Ye Q; Wang HJ; Deng YQ; Zhu SY; Zhang Y; Li SH; Qin CF
    Vaccine; 2014 May; 32(23):2675-81. PubMed ID: 24709585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
    Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
    J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.
    Monath TP; Myers GA; Beck RA; Knauber M; Scappaticci K; Pullano T; Archambault WT; Catalan J; Miller C; Zhang ZX; Shin S; Pugachev K; Draper K; Levenbook IS; Guirakhoo F
    Biologicals; 2005 Sep; 33(3):131-44. PubMed ID: 15975826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
    Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP
    J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.